HMGB2在ESCC患者外周血T细胞中的表达与临床病理指标的关系

Expression of HMGB2 in peripheral blood T cells of ESCC patients and its relationship with clinicopathological parameters

目的研究HMGB2在ESCC患者外周血T细胞中的表达水平及与临床病理指标的关系。方法以31例ESCC患者和13名健康人为研究对象,通过流式细胞术、RT-qPCR和Western blotting检测HMGB2在外周血T细胞中的表达情况;根据肿瘤分期和组织分化程度分组,评估HMGB2与病理指标的关系。结果与健康对照组相比,HMGB2在ESCC患者CD4^(+)和CD8^(+)T细胞中高表达。肿瘤Ⅰ~Ⅱ期组和Ⅲ~Ⅳ期组,高、中分化组和低分化组HMGB2表达率均显著高于健康对照组。临床病理结果显示,HMGB2的表达水平:低分化组高于高、中分化组;肿瘤组织>5 cm组高于肿瘤组织≤5 cm组,浸润深度T_(3)~T_(4)组高于T_(1)~T_(2)组,临床TNM分期Ⅲ~Ⅳ期组高于Ⅰ~Ⅱ期组。结论HMGB2在ESCC患者T细胞中高表达,其表达与ESCC患者的临床TNM分期、组织学分化程度、肿瘤大小、浸润深度均呈正相关。HMGB2可作为评价ESCC患者预后的潜在生物标志物和治疗靶点。

Objective To study the expression level and clinical significance of high mobility group protein B2(HMGB2)in peripheral blood T lymphocytes of patients with esophageal squamous cell carcinoma(ESCC).Methods The expression of HMGB2 in peripheral blood T lymphocytes was detected by flow cytometry,RT-qPCR and Western blotting in 31 ESCC patients and 13 healthy subjects.The relationship between HMGB2 and pathological indexes was evaluated according to tumor stage and tissue differentiation.Results Compared with healthy controls,HMGB2 was highly expressed in CD4^(+)and CD8^(+)T cells in ESCC patients.The expression rate of HMGB2 in tumor stageⅠ-ⅡandⅢ-Ⅳgroups,as well as high,middle differentiation and low differentiation groups were significantly higher than those in healthy control group.The clinicopathological analysis showed that the expression rate of HMGB2 was higher in the low differentiation group than that in the high,middle differentiation group;the group with tumor tissue>5 cm was higher than that with tumor tissue≤5 cm;the infiltration depth of T_(3)-T_(4) group was higher than that of T_(1)-T_(2) group;the clinical TNM stageⅢ-Ⅳgroup was higher than the stageⅠ-Ⅱgroup.Conclusion HMGB2 is highly expressed in T lymphocyte subsets of ESCC patients,and its expression is positively correlated with clinical TNM stage,histological differentiation degree,tumor size and invasion depth of ESCC patients.HMGB2 can be used as a potential biomarker and therapeutic target to evaluate the prognosis of ESCC patients.